A glutamine metabolism gene signature with prognostic and predictive value for colorectal cancer survival and immunotherapy response.

ABSTRACT:

Background

Colorectal cancer (CRC) remains a major cause of cancer mortality, and dysregulated glutamine metabolism has emerged as a potential therapeutic target. However, the precise role of glutamine in CRC progression and treatment response remains debated.

Methods

The authors collected transcriptome and microbiome information, from multiple sources to construct the GLMscore, a prognostic signature in CRC. To comprehensively characterize the biological features of GLMscore groups, the integration of transcriptomic profiling, KEGG pathway enrichment analysis, immune infiltration analysis, tumor immune microenvironment characterization, microbiome analysis, and tissue imaging were applied. Furthermore, CRC patients were stratified into GLMscore high and GLMscore low groups.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12119274 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature